PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics


0.78 (+6.74%)

POWR Rating

Component Grades













Add PHAT to Watchlist
Sign Up

Industry: Biotech



in industry

PHAT Stock Price Chart Interactive Chart >

Price chart for PHAT

PHAT Price/Volume Stats

Current price $12.36 52-week high $19.95
Prev. close $11.58 52-week low $6.09
Day low $11.37 Volume 521,211
Day high $13.44 Avg. volume 506,106
50-day MA $9.85 Dividend yield N/A
200-day MA $9.76 Market Cap 514.44M


Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.

PHAT Latest News Stream

Event/Time News Detail
Loading, please wait...

PHAT Latest Social Stream

Loading social stream, please wait...

View Full PHAT Social Stream

Latest PHAT News From Around the Web

Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | January 24, 2023

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data expected to provide the basis for future regulatory submission for vonoprazan as a daily treatment for patients with NERD, pending completion of 20-week safety extension periodOver 45 million people in the U.S. are estimated to have NERD, the largest subcategory of gastroesophageal reflux disease (GERD)

Yahoo | January 8, 2023

The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax

Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.

Yahoo | January 6, 2023

Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More

Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.

Yahoo | January 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | January 4, 2023

Read More 'PHAT' Stories Here

PHAT Price Returns

1-mo 21.65%
3-mo 18.39%
6-mo 34.20%
1-year -23.70%
3-year -67.45%
5-year N/A
YTD 10.16%
2022 -42.96%
2021 -40.79%
2020 6.68%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7356 seconds.